GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medtronic PLC (NYSE:MDT) » Definitions » Altman Z2-Score

Medtronic (Medtronic) Altman Z2-Score : 3.88 (As of Apr. 25, 2024)


View and export this data going back to 1980. Start your Free Trial

What is Medtronic Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Medtronic has a Altman Z2-Score of 3.88, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Medtronic's Altman Z2-Score or its related term are showing as below:

MDT' s Altman Z2-Score Range Over the Past 10 Years
Min: 2.88   Med: 3.78   Max: 6.25
Current: 3.88

During the past 13 years, Medtronic's highest Altman Z2-Score was 6.25. The lowest was 2.88. And the median was 3.78.


Medtronic Altman Z2-Score Historical Data

The historical data trend for Medtronic's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medtronic Altman Z2-Score Chart

Medtronic Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.77 3.57 3.64 3.74 3.82

Medtronic Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.50 3.82 3.83 3.86 3.88

Competitive Comparison of Medtronic's Altman Z2-Score

For the Medical Devices subindustry, Medtronic's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medtronic's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Medtronic's Altman Z2-Score falls into.



Medtronic Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Medtronic's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.14+3.26*0.3375+6.72*0.0686+1.05*1.3335
=3.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Jan. 2024:
Total Assets was $90,836 Mil.
Total Current Assets was $22,513 Mil.
Total Current Liabilities was $9,793 Mil.
Retained Earnings was $30,661 Mil.
Pre-Tax Income was 1472 + 1313 + 1196 + 1551 = $5,532 Mil.
Interest Expense was -188 + -180 + -148 + -187 = $-703 Mil.
Total Liabilities was $38,840 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(22513 - 9793)/90836
=0.14

X2=Retained Earnings/Total Assets
=30661/90836
=0.3375

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(5532 - -703)/90836
=0.0686

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(51792 - 0)/38840
=1.3335

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Medtronic has a Altman Z2-Score of 3.88 indicating it is in Safe Zones.


Medtronic  (NYSE:MDT) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Medtronic Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Medtronic's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Medtronic (Medtronic) Business Description

Address
Lower Hatch Street, 20 On Hatch, Dublin, IRL, 2
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
Executives
Brett A. Wall officer: EVP & Group Pres Restora Thera 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Gregory L Smith officer: EVP Global Ops & Supply Chain 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Michael Marinaro officer: EVP & President, Surgical OU 710 MEDTRONIC PARKWAY NE, LC300, MINNEAPOLIS MN 55432
Hoedt Rob Ten officer: EVP & President EMEAC 710 MEDTRONIC PKWY, MSLC300, MINNEAPOLIS MN 55432
Gregory P Lewis director C/O HONEYWELL INTERNATIONAL INC., 300 SOUTH TRYON STREET, CHARLOTTE NC 28202
Sean Salmon officer: EVP & Group President Diabetes MEDTRONIC PLC, 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Lidia Fonseca director 358 SOUTH MAIN STREET, BURLINGTON NC 27215
Karen L Parkhill officer: EVP & Chief Financial Officer 1717 MAIN STREET, MC 6402, DALLAS TX 75201
Ivan K Fong officer: EVP GENERAL COUNSEL & SECR 3M CENTER, ST. PAUL MN 55144-1000
Robert John White officer: EVP & President MITG MEDTRONIC PLC, 710 MEDTRONIC PKWY MS LC300, MINNEAPOLIS MN 55432
Richard H Anderson director MEDTRONIC, INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Bradley E Lerman officer: SVP General Counsel & Corp Sec MEDTRONIC, INC., 710 MEDTRONIC PKWY MSLC300, MINNEAPOLIS MN 55432
Geoffrey Martha officer: Sr VP, Strategy & Bus Dev 710 MEDTRONIC PKWAY, MS LC300, MINNEAPOLIS MN 55432
Jennifer M Kirk officer: Chief Accounting Officer 5 GREENWAY PLAZA, SUITE 110, HOUSTON TX 77046
John R Liddicoat officer: EVP & President of Americas MEDTRONIC PLC, 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432

Medtronic (Medtronic) Headlines

From GuruFocus

Q4 2023 Medtronic PLC Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Medtronic PLC Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Medtronic PLC Earnings Call Transcript

By GuruFocus Research 01-23-2024

Medtronic PLC Investor Briefing Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Medtronic PLC Earnings Call Transcript

By GuruFocus Research 01-23-2024